332154-57-1

Basic information

• Product Name: (4-CHLOROCARBONYLPHENYL)BORONIC ANHYDRIDE
• Synonyms: p-Chlorocarbonylphenylboronic Acid;Boronic acid, B-[4-(chlorocarbonyl)phenyl]-;4-Chlorocarbonylphenylboronic boronic acid;(4-CHLOROCARBONYLPHENYL)BORONIC ANHYDRIDE;4-BORONOBENZOYL CHLORIDE;Boronic acid, [4-(chlorocarbonyl)phenyl]- (9CI);4-Chlorocarbonylbenzeneboronic anhydride, tech. 90%
• CAS NO: 332154-57-1
• Molecular Formula: C₇H₆BClO₃
• Molecular Weight: 166.37
• Product Categories: ACIDHALIDE;blocks;BoronicAcids;Carboxes;Boronic acid
• Mol File: 332154-57-1.mol

Chemical Properties

• Melting Point: >300℃
• Boiling Point: 350.943 °C at 760 mmHg
• Flash Point: 166.045 °C
• Appearance: /
• Density: 1.397 g/cm³
• PKA: 7.08±0.10(Predicted)
• CAS DataBase Reference: (4-CHLOROCARBONYLPHENYL)BORONIC ANHYDRIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (4-CHLOROCARBONYLPHENYL)BORONIC ANHYDRIDE(332154-57-1)
• EPA Substance Registry System: (4-CHLOROCARBONYLPHENYL)BORONIC ANHYDRIDE(332154-57-1)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36
• Hazardous Substances Data: 332154-57-1(Hazardous Substances Data)

Usage

Uses

suzuki reaction

InChI:InChI=1/C7H4BClO2/c9-7(10)5-1-3-6(8-11)4-2-5/h1-4H

Upstream product

• 79-37-8 oxalyl dichloride 
• 14047-29-1 4-carboxyphenylboronic acid 
• 5720-05-8 4-methylphenylboronic acid 

Downstream Products

• 1186390-15-7 C₁₉H₃₃BN₂O₄Si 
• 1550000-22-0 C₄₃H₆₅BO₃₃ 
• 1550000-26-4 C₄₉H₇₅BO₃₈ 
• 1611473-73-4 4-(hexylcarbamoyl)phenylboronic acid 
• 389621-84-5 4-(morpholine-4-carbonyl)phenylboronic acid 
• 674299-31-1 4'-amino-3'-cyano-biphenyl-4-carboxylic acid dimethylamide 
• 674299-32-2 4'-amino-3'-(1H-tetrazol-5-yl)-biphenyl-4-carboxylic acid dimethylamide 
• 850568-12-6 4-(N-ethylaminocarbonyl)phenylboronic acid 
• 1186390-17-9 C₃₈H₄₅FN₈O₃Si 
• 405520-68-5 4-(N,N-dimethylaminocarbonyl)phenylboronic acid 

Relevant articles and documents

Enhanced Sensitivity for Hydrogen Peroxide Detection: Polydiacetylene Vesicles with Phenylboronic Acid Head Group

It was recently reported that, besides UV irradiated polymerization, polymerization of diacetylene compounds could also been initiated by radicals generated from enzyme catalyzed hydrogen peroxide (H2O2) decomposition. A new optical

Synthesis, spectroscopic characterization and theoretical studies of (4-boronobenzoyl)serine

(4-boronobenzoyl)serine (4BBS) was synthesized and investigated theoretically and experimentally by spectroscopic methods such as FT-IR, Raman and NMR. The molecular structure, spectroscopic parameters and geometric parameters were determined by computati

Carboxylic acid recognition of an N-ethyl-substituted diamidine having a diphenylnaphthalene unit in competing protic solvents

A new diphenylnaphthalene-based diamidine (1) having an N-ethyl-substituent to improve its solubility has been designed and synthesized for the recognition of dicarboxylic acids. The diamidine 1 forms 1:1 complexes with the α,ω-dicarboxylic acids in the competing protic solvent, MeOH, using the charge-assisted hydrogen bonding (i.e., formation of amidinium-carboxylate), and the formation of the complexes was determined by 1H NMR and DOSY NMR spectroscopies in a high concentration (2.0 mM). However, at a low concentration (25 μM), the turn-on fluorescence detection of the dicarboxylic acids was not successful because the diamidine 1 emits in MeOH before recognizing the carboxylic acids. Interestingly, the diamidine 1 does not emit in 2-propanaol before recognizing the α,ω-dicarboxylic acids, and succeeded in the detection of a dicarboxylic acid (turn-on response) in the protic solvent, 2-propanol. The interesting tight binding of the diamidine 1 with α,ω-dicarboxylic acids was observed in 2-propanol-d8 using 1H NMR and the restriction of the rotation of the phenyl rings of the 1,8- diphenylnaphthalene unit was also observed. These fluorescence and binding characteristics of the N-ethyl-substituted diamidine 1 are applicable for the detection of carboxylic acids in a protic solvent.

INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring C, X1, X2, L1, R1, R2, R3, R4, R5, R6, R7, m and n are as defined herein, which are useful as MAP4K1 inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by MAP4K1.

A succinimide containing phenylo boric acid functional polyurethane and its preparation method (by machine translation)

A succinimide containing phenylo boric acid functional polyurethane and its preparation method, the raw material is used for the 4 [...]carboxyl group benzene boric acid and its ortho, meta or para-derivatives, the first β alanine substitution reaction to produce amide, DCC activated carboxyl group for, and N-hydroxysuccinimide esterification reaction, to obtain corresponding succinimide ester. Its structural formula is: In the formula: R is H, X (X is F, Cl, Br, I) or NO 2. The advantage of this invention is to: high efficiency, the use of mild conditions, can be used for physiological conditions or under large biological molecule of the modification of the biological interface. Using this method, the pH response of the phenylboronic acid, sugar response introduced into the biological system. (by machine translation)

IRE-1α INHIBITORS

PROBLEM TO BE SOLVED: To provide compounds which directly inhibit inositol requiring enzyme 1 (IRE-1α activity) in vitro, prodrugs, and pharmaceutically acceptable salts thereof. SOLUTION: The present invention provides a compound represented by formula (A) [R3 and R4 are H or the like; Q5-Q8, together with the benzene ring to which they are attached, form a benzofused ring, where at least one of Q5-Q8 is a heteroatom selected from N, O, and S. COPYRIGHT: (C)2016,JPOandINPIT

SUBSTITUTED 1,6-NAPHTHYRIDINES

The present invention relates to the use of compounds of general formula (I) wherein R' is hydrogen or lower alkyl; R1 is halogen, lower alkyl, cycloalkyl or cyano; or is phenyl, optionally substituted by one to three substituents, selected from lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, halogen, cyano, hydroxy, C(O)-NH-lower alkyl, CH2-C(O)-NH-lower alkyl, CH2-NH-C(O)-lower alkyl, CH2NH2, S(O)2CH3, S(O)2N(CH3)2, or by heterocycloalkyl groups; or is pyrazol-1, 4 or 5-yl, optionally substituted by lower alkyl; or is thiazol-5-yl, optionally substituted by one or two lower alkyl groups; or is pyridine 2, 3 or 4-yl, optionally substituted by lower alkyl, lower alkoxy, halogen or N(CH3)2; or is 3,6-dihydro-2H-pyran; or is benzo[d][1,3]dioxol-5-yl; or is 2,3-dihydrobenzo[b][1,4]dioxin-6-yl; R2 is hydrogen, lower alkyl or lower alkyl substituted by alkoxy; R3 is hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, NH-S(O)2-CH3, -(CH2)m-O-lower alkyl or -(CH2)n-S(O)2-CH3; or is -(CR2)n-phenyl, optionally substituted by -S(O)2CH3 or lower alkoxy; or is -(CH2)n-heterocycloalkyl, optionally substituted by lower alkyl and =O; or is -(CH2)n-heteroaryl, optionally substituted by one or two lower alkyl groups; or is -(CH2)n-cycloalkyl, optionally substituted by cyano; or R2 and R3 form together with the N atom to which they are attached a heterocyclic ring, selected from morpholine, piperidine, 1, 1-dioxo-thiomorpholine or piperazine which may be substituted by lower alkyl or C(O)O-lower alkyl, or may form a pyrrolidine ring, optionally substituted by hydroxy; R is independently from n hydrogen or lower alkyl; n is 0, 1, 2, 3; m is 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof, for the treatment of schizophrenia, obsessive-compulsive personality disorder, depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction ("chemobrain"), Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs selected from alcohol, opiates, methamphetamine, phencyclidine or cocaine.

TARGETED NANOPARTICLES

Described herein are carrier nanoparticles comprising a polymer containing a polyol coupled to a polymer containing a boronic acid, configured to present the polymer containing a boronic acid to an environment external to the nanoparticle. Targeted versions of the described nanoparticles are also described, as are related compositions, methods and systems.

AURORA KINASE INHIBITORS

Disclosed herein are Aurora kinase Inhibitors represented by Structural Formula (I): Values for the variables in Structural Formula (I) are defined herein.

DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS

The present invention relates to novel diarylurea derivatives useful as chloride channel blockers. In other aspects the invention relates to the use of these compounds in a method for therapy, such as for the treatment of bone metabolic diseases, diseases responsive to modulation of the mast cell or basophil activity, diseases responsive to inhibition of angiogenesis, or sickle cell anaemia, and to pharmaceutical compositions comprising the compounds of the invention.